주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기
통합검색
로그인
고객센터
주요메뉴
질환포커스
세계의약뉴스
국내의약뉴스
성상변경내역
약제급여기준 개정내역
제약업계 소식
메디컬포커스
컨퍼런스
CME
근골격계
남성건강
내분비대사계
면역계
비뇨기계
뇌심혈관계
종양
호흡기계
감각기관계
중추신경계
소화기계
감염계
혈액 및 조혈계
미용
기타
최근 해외학술대회의 주요 발표내용을 제공합니다.
컨퍼런스 커버리지
American Society of Nephrology (ASN) Kidney Week 2025
05 November - 09 November, 2025, United States
Tenapanor relieves constipation in ESKD patients with hyperphosphataemia
2025-12-10
Individuals with end-stage kidney disease (ESKD) who have mild-to-severe constipation obtain relief from tenapanor in the post hoc analysis of the phase III BLOCK study.
Telitacicept reduces proteinuria in adults with IgA nephropathy
2025-12-10
Treatment with telitacicept led to a significant reduction in proteinuria
among patients with immunoglobulin A nephropathy (IgAN) compared with placebo, according to a phase III study presented at ASN Kidney Week 2025.
Atacicept for IgA nephropathy succeeds in phase III trial
2025-12-10
Treatment with the self-administered atacicept injectable yields a significant reduction in proteinuria in patients with IgA nephropathy, according to interim data from the phase III ORIGIN 3 trial.
Sparsentan remains superior to irbesartan for IgAN in post hoc analysis
2025-12-10
In the post hoc analysis of the phase III PROTECT trial, the non-immunosuppressive dual endothelin angiotensin receptor antagonist sparsentan remains superior to irbesartan for the treatment of immunoglobulin A nephropathy (IgAN).
Conservative dialysis strategy promotes faster kidney function recovery in severe AKI
2025-12-10
In hospitalized patients with acute kidney injury (AKI) requiring dialysis (AKI-D), a conservative strategy appears to lead to more frequent and faster kidney function recovery with fewer dialysis sessions compared with a conventional strategy, as shown in the LIBERATE-D trial.
Tirzepatide may reduce major kidney events in T2D patients with CVD, CKD
2025-12-10
The use of tirzepatide appears to reduce decline in kidney function, prevent albuminuria progression, and lower the risk of the composite kidney outcome compared with dulaglutide in patients with
type 2 diabetes
(T2D), atherosclerotic cardiovascular disease (ASCVD), and very high-risk chronic kidney disease (CKD), reports a study presented at Kidney Week 2025.
1
최근 본 콘텐츠
최근 본 콘텐츠가 없습니다
관심제품
관심콘텐츠
